Candidiasis yeast infection vulvovaginitis
Pro Research Analysisby 
Searched over 200M research papers
Understanding Vulvovaginal Candidiasis (VVC): Causes, Diagnosis, and Treatment
Prevalence and Impact of Vulvovaginal Candidiasis
Vulvovaginal candidiasis (VVC) is a common infection affecting the lower female genital tract, primarily caused by the yeast species Candida albicans and other non-albicans species Van Schalkwyk2015Nyirjesy2022Sustr2020. It is estimated that up to 75% of women will experience VVC at least once in their lifetime, with 20% experiencing recurrent infections Van Schalkwyk2015Tressler2021Carvalho2021. The condition significantly impacts quality of life, mental health, and sexual activity .
Pathogenesis and Virulence Factors
Candida species are part of the normal mucosal flora but can become pathogenic under favorable conditions, leading to symptomatic VVC . Key virulence factors include phenotypic switching, biofilm formation, and the ability to invade vaginal epithelial cells Czechowicz2022Rodríguez-Cerdeira2019. Biofilms, in particular, provide resistance to antifungal treatments, complicating the management of VVC .
Diagnosis of Vulvovaginal Candidiasis
Diagnosis of VVC typically involves yeast culture, which remains the gold standard . Newer molecular assays have also been developed and perform well in diagnosing VVC . Accurate identification of the causative species is crucial for guiding effective treatment, especially in cases of recurrent infections .
Treatment Options for VVC
Treatment for uncomplicated VVC primarily involves azole antifungals, which are effective in most cases Van Schalkwyk2015Nyirjesy2022. For recurrent VVC, maintenance therapy with weekly oral fluconazole for up to six months is recommended . New treatment options, such as TOL-463 and ibrexafungerp, have shown promise in clinical trials . For infections caused by non-albicans species, boric acid has been found useful .
Special Considerations in Treatment
Pregnancy and HIV present special challenges in the treatment of VVC. Fluconazole use during pregnancy may be associated with risks such as spontaneous abortion and congenital defects, necessitating careful consideration . In women with HIV, lower CD4+ T-cell counts are associated with increased rates of VVC, and treatment protocols are similar to those for women without HIV .
Recurrent Vulvovaginal Candidiasis (RVVC)
Recurrent VVC (RVVC) is defined as four or more episodes per year and affects up to 9% of women in different populations Van Schalkwyk2015Blostein2017Rosati2020. Factors contributing to RVVC include younger age, lower BMI, and higher probiotic use . The condition is often linked to a local mucosal overreaction of the immune system rather than a defective host response .
Conclusion
Vulvovaginal candidiasis is a prevalent and impactful condition that requires accurate diagnosis and effective treatment strategies. Understanding the pathogenesis, virulence factors, and special considerations in treatment can help manage and reduce the incidence of VVC and RVVC. Ongoing research and new treatment options continue to improve outcomes for affected women.
Sources and full results
Most relevant research papers on this topic
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.
Vulvovaginal candidiasis can be effectively managed with topical and oral antifungal azole medications, with partner treatment enhancing cure rates for trichomoniasis.
DOI
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
The 2021 CDC STI Treatment Guidelines for Vulvovaginal Candidiasis reflect new knowledge and changes in treatment recommendations, with yeast culture as the gold standard for diagnosis and new treatments like TOL-463 and ibrexafungerp for recurrent cases.
DOI